- Home
- MSN vs CANF Comparison
MSN vs CANF Comparison
Compare MSN & CANF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MSN | CANF |
|---|---|---|
| Founded | 1948 | 1994 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Consumer Electronics/Appliances | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.3M | 6.0M |
| IPO Year | 1995 | 2011 |
Fundamental Metrics
Financial Performance| Metric | MSN | CANF |
|---|---|---|
| Price | $0.36 | $3.27 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $50.00 |
| AVG Volume (30 Days) | 31.6K | ★ 1.8M |
| Earning Date | 02-17-2026 | 03-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 9.09 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $77,829,000.00 | N/A |
| Revenue This Year | N/A | $2,715,455.50 |
| Revenue Next Year | N/A | $101.06 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.32 | $0.17 |
| 52 Week High | $0.85 | $10.40 |
Technical Indicators
Market Signals| Indicator | MSN | CANF |
|---|---|---|
| Relative Strength Index (RSI) | 45.69 | 50.45 |
| Support Level | $0.35 | $2.88 |
| Resistance Level | $0.42 | $3.42 |
| Average True Range (ATR) | 0.02 | 0.51 |
| MACD | 0.00 | 0.04 |
| Stochastic Oscillator | 46.72 | 21.64 |
Price Performance
Historical ComparisonAbout MSN Emerson Radio Corporation
Emerson Radio Corp operates in the consumer electronics industry. The company designs, sources, imports, and markets a variety of houseware and consumer electronic products, and licenses the Emerson trademark domestically and internationally. The products offered by the company are televisions, digital versatile disc players and video cassette recorders, audio accessories, microwave ovens, home theatres, high-end audio products, office products, mobile stereo, and wireless products.
About CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)
Can Fite Biopharma Ltd is a clinical-stage biopharmaceutical company. The company focuses on developing orally bioavailable small-molecule drugs targeting the A3 adenosine receptor for treating cancer, inflammatory diseases, liver disorders, and related conditions. It has a pipeline of proprietary drug candidates in Phase II and Phase III clinical development. The company's platform targets the A3 adenosine receptor (A3AR), which is more expressed in inflammatory and cancerous cells than in normal cells. Its pipeline drugs include Namodenoson, Piclidenoson, CF602, and Cannabinoids.